GO:0097138 BAD-BCL-2 complex: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0097138 (BAD-BCL-2 complex) is a cellular_component term describing a heterodimeric protein complex of the proapoptotic BH3-only protein BAD and the antiapoptotic effector BCL-2.
• The complex forms at mitochondria and acts as a molecular switch that integrates survival signaling, glycolysis and apoptosis.
• BAD is regulated by phosphorylation, including cAMP-dependent protein kinase phosphorylation of Ser155, which controls its interaction with BCL-2 family proteins.
• BAD can also cooperate with p53, forming a Bad/p53 complex at mitochondria to induce apoptosis.
• Dysregulation of BAD-BCL-2 complex biology is linked to cancer, cardiomyocyte injury, bipolar disorder and other conditions.
• CRISPR knockout, point-mutation, knock-in and overexpression models enable causal dissection of BAD-BCL-2 complex function in disease.
Description
The BAD-BCL-2 complex (GO:0097138) is a heterodimeric protein complex consisting of BAD and BCL-2, members of the Bcl-2 family of anti- and proapoptotic regulators. BAD is a BH3-only proapoptotic protein, whereas BCL-2 is an antiapoptotic effector; their physical association at mitochondria is a central node in the decision between cell survival and apoptosis. Because this complex integrates signals from growth factor, metabolic and stress pathways, it is a high-value target for understanding how cells commit to death. Molecular modeling of the BAD complex in the mitochondrion has suggested that it integrates glycolysis and apoptosis, positioning GO:0097138 as a metabolic-apoptotic interface rather than a simple binary switch. BAD phosphorylation by cAMP-dependent protein kinase at Ser155 regulates its interaction with BCL-2 family members, providing a mechanistic handle for experimental perturbation. In parallel, BAD is transcriptionally upregulated by p53 and can form a Bad/p53 complex at mitochondria to induce apoptosis, expanding the functional repertoire of BAD beyond canonical BCL-2 binding. For researchers, GO:0097138 matters because it connects cell death machinery to disease phenotypes. For example, 14-3-3γ attenuates lipopolysaccharide-induced cardiomyocyte injury through the Bcl-2 family/mitochondria pathway, a process in which BAD-BCL-2 balance is central. Negative regulation of NaF-induced apoptosis by a Bad-CAII complex further illustrates how BAD-containing complexes tune stress responses. In cancer, knocking down SKA1 inhibits hepatocellular carcinoma progression via apoptosis, highlighting apoptotic control as a therapeutic axis. This article synthesizes QuickGO annotation and verified literature to provide a publication-ready overview of GO:0097138, its components, regulation, disease links and CRISPR-based research methods.
BAD-BCL-2 complex At A Glance
| GO ID | GO:0097138 |
|---|---|
| GO term | BAD-BCL-2 complex |
| Ontology | cellular_component |
| Synonym | None listed in QuickGO |
| Definition | A heterodimeric protein complex consisting of BAD and BCL-2, members of the Bcl-2 family of anti- and proapoptotic regulators |
| Major function | Integration of apoptotic and metabolic signaling at mitochondria through BAD-BCL-2 heterodimerization |
| Key components | BAD (BH3-only proapoptotic) and BCL-2 (antiapoptotic effector) |
| Subcellular context | Mitochondrion-associated complex |
| Regulatory modification | BAD phosphorylation, including PKA-mediated Ser155 phosphorylation |
What Is GO:0097138?
GO:0097138 (BAD-BCL-2 complex) is defined in QuickGO as a heterodimeric protein complex consisting of BAD and BCL-2, members of the Bcl-2 family of anti- and proapoptotic regulators. In practical terms, it is a cellular_component entity: a physical assembly of two proteins, BAD and BCL-2, that forms at mitochondria and participates in apoptotic signaling. The term has no listed synonyms in QuickGO.
Why Is BAD-BCL-2 complex Important in Cell Biology?
GO:0097138 is important because the BAD-BCL-2 heterodimer sits at the intersection of apoptosis, metabolism and stress signaling, and its perturbation is experimentally tractable with modern CRISPR approaches. Understanding this complex helps explain how cells interpret survival cues and how dysregulation contributes to cancer, cardiac injury and other diseases.
• Defines a specific heterodimeric complex rather than a generic Bcl-2 family interaction, enabling precise annotation.
• Links apoptotic machinery to glycolysis and mitochondrial metabolism.
• BAD phosphorylation at Ser155 by cAMP-dependent protein kinase regulates complex formation.
• BAD is transcriptionally upregulated by p53 and can form a Bad/p53 complex at mitochondria.
• 14-3-3γ modulates the Bcl-2 family/mitochondria pathway in cardiomyocyte injury.
• Bad-CAII complex negatively regulates NaF-induced apoptosis.
• Apoptotic control via BAD/BCL-2 axis is relevant to hepatocellular carcinoma progression.
• Oxidative phosphorylation collaborative activities involving BAD biology have been identified in bipolar disorder.
• Tuberin activates the proapoptotic molecule BAD, connecting TSC signaling to BAD function.
• CRISPR models allow causal testing of BAD-BCL-2 complex components in disease phenotypes.
Structure and Composition of BAD-BCL-2 complex
Heterodimerization of BAD and BCL-2
In simple terms: BAD and BCL-2 stick together to form a two-protein unit.
The defining feature of GO:0097138 is a heterodimeric protein complex consisting of BAD and BCL-2, members of the Bcl-2 family of anti- and proapoptotic regulators. Molecular modeling of the BAD complex in the mitochondrion has been used to understand how this heterodimer integrates glycolysis and apoptosis. The complex is therefore a cellular_component entity whose composition is defined by the physical association of these two proteins.
Mitochondrial localization
In simple terms: The BAD-BCL-2 pair works at the mitochondria, the cell's power plants.
The BAD complex has been modeled as residing in a mitochondrion, integrating glycolysis and apoptosis. Consistent with a mitochondrial site of action, BAD is transcriptionally upregulated by p53 and forms a Bad/p53 complex at the mitochondria to induce apoptosis. This mitochondrial context is central to the function of GO:0097138.
BAD as a BH3-only proapoptotic component
In simple terms: BAD is the 'death-promoting' half of the pair.
BAD is a proapoptotic Bcl-2 family member whose activity is regulated by phosphorylation. cAMP-dependent protein kinase regulates BAD via phosphorylation of a novel site, Ser155. Tuberin activates the proapoptotic molecule BAD, further linking upstream signaling to BAD function. These findings establish BAD as the proapoptotic component of the GO:0097138 heterodimer.
BCL-2 as the antiapoptotic partner
In simple terms: BCL-2 is the 'survival-promoting' half that BAD binds.
BCL-2 is an antiapoptotic regulator of the Bcl-2 family, and the GO:0097138 definition explicitly places BCL-2 as the partner of BAD in the heterodimer. The Bcl-2 family/mitochondria pathway is functionally relevant in cardiomyocyte injury, where 14-3-3γ attenuates lipopolysaccharide-induced damage through this pathway. This positions BCL-2 as the survival effector whose interaction with BAD defines the complex.
Assembly and dynamic regulation
In simple terms: The pair forms and breaks apart depending on chemical signals.
Assembly of the BAD-BCL-2 complex is dynamically regulated by phosphorylation of BAD, including PKA-mediated phosphorylation of Ser155. Additional BAD-containing complexes, such as Bad/p53 at mitochondria and Bad-CAII, illustrate that BAD participates in multiple context-dependent assemblies. The balance between these interactions determines apoptotic outcomes.
Key Genes Involved in GO:0097138 BAD-BCL-2 complex
The following genes and proteins are directly or functionally implicated in BAD-BCL-2 complex (GO:0097138) biology according to the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| BAD | Proapoptotic BH3-only component of the BAD-BCL-2 heterodimer | Core component of GO:0097138; regulated by phosphorylation at Ser155 |
| BCL-2 | Antiapoptotic effector and partner of BAD in the heterodimer | Defining component of GO:0097138 |
| PKA (cAMP-dependent protein kinase) | Phosphorylates BAD at Ser155 to regulate complex formation | Upstream regulator of BAD-BCL-2 interaction |
| TP53 (p53) | Transcriptionally upregulates BAD and forms Bad/p53 complex at mitochondria | Links p53 stress signaling to BAD-mediated apoptosis |
| CAII (carbonic anhydrase II) | Forms Bad-CAII complex that negatively regulates NaF-induced apoptosis | Context-dependent BAD complex partner |
| YWHAG (14-3-3γ) | Attenuates LPS-induced cardiomyocyte injury via Bcl-2 family/mitochondria pathway | Modulates BAD-BCL-2 axis in cardiac injury |
| TSC2 (tuberin) | Activates the proapoptotic molecule BAD | Connects TSC signaling to BAD function |
| SKA1 | Knockdown inhibits hepatocellular carcinoma progression via apoptosis | Apoptosis-related cancer target linked to BAD/BCL-2 biology |
| OXPHOS-related genes | Collaborative activities with oxidative phosphorylation identified in bipolar disorder | Metabolic context of BAD biology |
| BCL-2 family members | Anti- and proapoptotic regulators forming the family context of GO:0097138 | Family-level framework for BAD-BCL-2 studies |
| Mitochondrial apoptosis effectors | Downstream execution of mitochondrial apoptosis | Functional readout of BAD-BCL-2 complex activity |
| Glycolysis-related proteins | Integrated with BAD complex function at mitochondria | Metabolic-apoptotic crosstalk |
How Is BAD-BCL-2 complex Regulated?
BAD-BCL-2 complex formation is regulated by phosphorylation of BAD. cAMP-dependent protein kinase regulates BAD via phosphorylation of a novel site, Ser155, which controls BAD interaction with BCL-2 family proteins. Tuberin activates the proapoptotic molecule BAD, providing an upstream signaling input. In addition, 14-3-3γ modulates the Bcl-2 family/mitochondria pathway in cardiomyocytes, indicating that scaffold proteins can influence the BAD-BCL-2 axis. p53 transcriptionally upregulates BAD and forms a Bad/p53 complex at mitochondria, adding a transcriptional and protein-protein interaction layer of regulation. Finally, Bad-CAII complex formation negatively regulates NaF-induced apoptosis, showing that alternative BAD partners can modulate the pathway.
BAD-BCL-2 complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SKA1 | Hepatocellular carcinoma progression via apoptosis | CRISPR knockout in HCC cell lines and in vivo validation |
| YWHAG (14-3-3γ) | LPS-induced cardiomyocyte injury via Bcl-2 family/mitochondria pathway | Overexpression and knockout in cardiomyocytes |
| BAD | Apoptosis regulation and metabolic integration | Point mutation at Ser155 and knockout models |
| TP53 (p53) | Stress-induced apoptosis with Bad/p53 complex at mitochondria | Knockout and knock-in models |
| TSC2 (tuberin) | BAD activation and TSC-related signaling | Knockout and overexpression models |
Cancer and apoptosis evasion
Apoptotic control through BAD and BCL-2 family proteins is central to cancer biology. Knocking down SKA1 inhibits hepatocellular carcinoma progression via apoptosis, demonstrating that apoptotic machinery can be therapeutically targeted in liver cancer. Because GO:0097138 represents a heterodimer of proapoptotic BAD and antiapoptotic BCL-2, its balance is mechanistically relevant to tumor cell survival decisions.
Cardiomyocyte injury and inflammation
14-3-3γ protein attenuates lipopolysaccharide-induced cardiomyocyte injury through the Bcl-2 family/mitochondria pathway. This places the BAD-BCL-2 complex within the mitochondrial pathway of cardiac cell death during inflammatory stress. Modulating this axis may therefore be relevant to cardioprotection research.
Metabolic and neuropsychiatric contexts
Molecular modeling of the BAD complex in the mitochondrion has linked it to integration of glycolysis and apoptosis. In bipolar disorder, collaborative activities with oxidative phosphorylation have been identified, suggesting metabolic-apoptotic crosstalk involving BAD biology. These findings support a broader role for GO:0097138 beyond classical apoptosis.
Stress-induced apoptosis and alternative BAD complexes
Bad-CAII complex negatively regulates NaF-induced apoptosis, showing that BAD participates in stress-specific complexes that modulate cell death. BAD is also transcriptionally upregulated by p53 and forms a Bad/p53 complex at mitochondria to induce apoptosis. Together, these studies indicate that the BAD-BCL-2 complex operates within a network of context-dependent BAD interactions relevant to stress and disease.
From BAD-BCL-2 complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is BAD required for BAD-BCL-2 complex formation? | BAD knockout cell model |
| Does Ser155 phosphorylation control BAD-BCL-2 interaction? | BAD Ser155 point-mutation knock-in |
| Does p53-BAD cooperation drive mitochondrial apoptosis? | TP53 knockout and BAD knock-in models |
| Can BCL-2 overexpression block BAD-mediated apoptosis? | BCL-2 overexpression cell model |
| Does 14-3-3γ modulate the Bcl-2 family/mitochondria pathway? | YWHAG overexpression and knockout in cardiomyocytes |
| Is SKA1 causally involved in HCC apoptosis? | SKA1 knockout in HCC models |
How to Study the BAD-BCL-2 complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Co-immunoprecipitation | Physical BAD-BCL-2 interaction | Detecting GO:0097138 complex formation |
| Phospho-immunoblotting | BAD phosphorylation status | Assessing PKA-mediated Ser155 phosphorylation |
| Apoptosis assay | Cell death and caspase activity | Functional readout of BAD-BCL-2 complex |
| Mitochondrial membrane potential assay | Mitochondrial integrity | Evaluating Bcl-2 family/mitochondria pathway |
| Metabolic profiling | Glycolysis and oxidative phosphorylation | Linking BAD complex to metabolism |
| Transcriptomics | Gene expression changes | Identifying downstream targets of BAD-BCL-2 perturbation |
| Proximity ligation assay | In situ protein-protein interaction | Confirming complex assembly at mitochondria |
Co-immunoprecipitation and proximity assays
Because GO:0097138 is defined by a physical heterodimer, co-immunoprecipitation of BAD and BCL-2 is a direct way to detect the complex. Proximity-based assays can complement this by measuring interaction in situ at mitochondria. These methods are essential for confirming that a candidate perturbation alters complex assembly.
Phosphorylation analysis
BAD regulation by phosphorylation, including PKA-mediated Ser155 phosphorylation, can be assessed by phospho-specific immunoblotting and mass spectrometry. Such analyses link upstream kinase activity to BAD-BCL-2 complex status. Tuberin-mediated BAD activation can also be monitored through phosphorylation readouts.
Apoptosis and mitochondrial function assays
Apoptosis assays, mitochondrial membrane potential measurements and caspase activity assays provide functional readouts of BAD-BCL-2 complex activity. In cardiomyocyte injury models, the Bcl-2 family/mitochondria pathway can be interrogated with these assays. In cancer models, apoptosis readouts after SKA1 knockdown illustrate this approach.
Transcriptomic and metabolic profiling
Since the BAD complex integrates glycolysis and apoptosis, metabolic profiling and transcriptomics can reveal downstream consequences of complex perturbation. Collaborative activities with oxidative phosphorylation have been identified in bipolar disorder, supporting metabolic profiling in relevant models. These approaches help connect GO:0097138 to cellular phenotypes.
How CRISPR Can Be Used to Study GO:0097138 BAD-BCL-2 complex
Knockout
CRISPR knockout of BAD or BCL-2 can abolish the BAD-BCL-2 complex and reveal its requirement for apoptosis and metabolic phenotypes. Knockout of upstream regulators such as TP53 or TSC2 can further dissect the pathway. Knockdown of SKA1 in hepatocellular carcinoma demonstrates the utility of loss-of-function approaches in apoptosis research.
Point Mutation
Point mutation of BAD at Ser155 can test whether PKA-mediated phosphorylation controls BAD-BCL-2 complex formation. Such models are ideal for separating phosphorylation-dependent from phosphorylation-independent functions. They also allow precise structure-function analysis of the heterodimer.
Knock-in
Knock-in of tagged BAD or BCL-2 enables detection and purification of the endogenous complex. Knock-in of disease-relevant variants can model how mutations affect complex assembly. These models support physiologically relevant studies of GO:0097138.
Overexpression
Overexpression of BCL-2 can shift the balance toward survival and block BAD-mediated apoptosis. Overexpression of 14-3-3γ attenuates cardiomyocyte injury through the Bcl-2 family/mitochondria pathway, illustrating gain-of-function approaches. Overexpression models complement knockout studies for bidirectional control of the pathway.
How EDITGENE Supports BAD-BCL-2 complex Research
Researchers studying BAD-BCL-2 complex-related genes often need to determine whether a candidate gene is causally involved in apoptosis, metabolism or disease phenotypes. EDITGENE provides the CRISPR tools and services required to build such causal evidence with rigor and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for BAD-BCL-2 complex research.
Frequently Asked Questions About BAD-BCL-2 complex
What is GO:0097138?
GO:0097138 is the Gene Ontology cellular_component term for the BAD-BCL-2 complex, a heterodimeric protein complex consisting of BAD and BCL-2, members of the Bcl-2 family of anti- and proapoptotic regulators.
What is the BAD-BCL-2 complex?
The BAD-BCL-2 complex is a heterodimer of the proapoptotic BH3-only protein BAD and the antiapoptotic effector BCL-2 that forms at mitochondria and regulates apoptosis.
What genes are involved in the BAD-BCL-2 complex?
The core genes are BAD and BCL-2; upstream regulators include PKA, TP53, TSC2 and YWHAG (14-3-3γ), and context-dependent partners include CAII.
Where does the BAD-BCL-2 complex form?
The BAD complex has been modeled as residing in a mitochondrion, integrating glycolysis and apoptosis, and BAD can form complexes at mitochondria with p53.
How is BAD regulated in the BAD-BCL-2 complex?
BAD is regulated by phosphorylation, including cAMP-dependent protein kinase phosphorylation of Ser155, which controls its interactions with BCL-2 family proteins.
What diseases are linked to BAD-BCL-2 complex biology?
Links include cancer such as hepatocellular carcinoma, LPS-induced cardiomyocyte injury, bipolar disorder and stress-induced apoptosis.
How can I study the BAD-BCL-2 complex with CRISPR?
CRISPR knockout, point mutation at BAD Ser155, tagged knock-in and BCL-2 overexpression are established strategies to dissect complex function.
Does p53 interact with BAD?
Yes, BAD is transcriptionally upregulated by p53 and forms a Bad/p53 complex at the mitochondria to induce apoptosis.
What is the role of 14-3-3γ in BAD-BCL-2 biology?
14-3-3γ protein attenuates lipopolysaccharide-induced cardiomyocyte injury through the Bcl-2 family/mitochondria pathway.
Can BAD form complexes other than BAD-BCL-2?
Yes, BAD can form a Bad/p53 complex at mitochondria and a Bad-CAII complex that negatively regulates NaF-induced apoptosis.
Conclusion
GO:0097138 (BAD-BCL-2 complex) is a precisely defined cellular_component term for a heterodimeric BAD-BCL-2 assembly that integrates apoptotic and metabolic signaling at mitochondria. Its regulation by BAD phosphorylation, its cooperation with p53 and its links to cancer, cardiac injury and neuropsychiatric contexts make it a compelling research target. CRISPR-based knockout, point-mutation, knock-in and overexpression models provide the causal toolkit needed to move from correlation to mechanism in BAD-BCL-2 complex biology. EDITGENE supports these efforts with end-to-end model generation, screening and bioinformatics services.
References
- 1. Yang J et al.. 2010. Molecular modeling of BAD complex resided in a mitochondrion integrating glycolysis and apoptosis.. J Theor Biol 266(2):231-41 PMID: 20540951
- 2. Liu D et al.. 2014. 14-3-3γ protein attenuates lipopolysaccharide-induced cardiomyocytes injury through the Bcl-2 family/mitochondria pathway.. Int Immunopharmacol 21(2):509-15 PMID: 24957688
- 3. Jiang P et al.. 2006. The Bad guy cooperates with good cop p53: Bad is transcriptionally up-regulated by p53 and forms a Bad/p53 complex at the mitochondria to induce apoptosis.. Mol Cell Biol 26(23):9071-82 PMID: 17000778
- 4. Otsuki S et al.. 2011. Negative regulation of NaF-induced apoptosis by Bad-CAII complex.. Toxicology 287(1-3):131-6 PMID: 21708216
- 5. Luo Q et al.. 2025. Knocking Down SKA1 Inhibits Hepatocellular Carcinoma Progression via Apoptosis: Integrating Single-Cell Transcriptomics With In Vivo and In Vitro Validation.. Biofactors 51(5):e70044 PMID: 40874684
- 6. Sawai H et al.. 2015. Identification of collaborative activities with oxidative phosphorylation in bipolar disorder.. Bioinformation 11(4):207-16 PMID: 26124562
- 7. Freilinger A et al.. 2006. Tuberin activates the proapoptotic molecule BAD.. Oncogene 25(49):6467-79 PMID: 16702951
- 8. Lizcano JM et al.. 2000. Regulation of BAD by cAMP-dependent protein kinase is mediated via phosphorylation of a novel site, Ser155.. Biochem J 349(Pt 2):547-57 PMID: 10880354
